RXi Pharmaceuticals Corporation, a biopharmaceutical company search



if (lexico_globals.googleafc.ads.content.length)
{
if (lexico_globals.googleafc.ads.content.length >= 4) {
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexic the progress and commercialization of proprietary therapeutics based on RNA retardation (RNAi), announced today that it has entered into a fact-finding synergy with Mirna Therapeutics (Austin, TX), to delimit the utility of combining RXi's proprietary rxRNA™ scientific knowledge with Mirna's microRNA mimics as budding therapeutics in oncology. The parties will each complemental applied science and nest egg* to the teams to originate and evaluate novel microRNA compounds.

More: - Continued here